Bradley kept at sector perform by RBC

RBC Capital Markets analyst Ken Trbovich maintained Bradley Pharmaceuticals Inc. at sector perform, speculative risk, and a $19 price target. The company reported third-quarter 2006 revenues of $35.2 million and a profit of $0.23 per share compared to the analyst's estimate of $38.1 million and $0.25 per share. Bradley's latest effort to in-license a late-stage project from BioSante Pharmaceuticals minimizes the near-term risk for Bradley by reducing the up front payment to $3.5 million and keeping total costs on approval under $10.5 million. Shares of the Fairfield, N.J.-based pharmaceutical company were up 80 cents, or 3.37%, at $18.43. (NYSE: BDY)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.